Source: http://www.asmscience.org/content/book/10.1128/9781555815639.ch23
Timestamp: 2019-04-20 02:33:29+00:00

Document:
In developing countries, the levels of quinolone resistance among gram-negative bacteria are very low, probably because of the low use of these antimicrobial agents, in association with their high cost. One of the most fundamental measures that could be taken to minimize quinolone resistance and antibiotic resistance in general is to eliminate supplementation of animal feeds with antibiotics, including tetracycline, macrolide, and quinolone derivatives. Escherichia coli is likely the Enterobacteriaceae in which the increase in quinolone resistance has been most evident. This trend in fluoroquinolone resistance has also been shown in Enterobacteriaceae from bacteremias from hospitals in England and Wales. Pseudomonas aeruginosa and Acinetobacter baumannii are the two most relevant nonfermentative gram-negative bacteria. They share similar characteristics, one being the ability to develop resistance to multiple antimicrobial agents. Quinolone resistance in enterococci has developed rapidly, and there are high rates of resistance, especially among vancomycin-resistant enterococci. In 1998, plasmid-mediated resistance in Klebsiella pneumoniae, caused by the qnrA gene, was reported. The future of the increase of quinolone resistance is difficult to predict, but it will clearly continue to increase unless steps are taken to reduce it, such as the development of SOS inhibitors.
Evolution of the chemical structure of the quinolones.
Evolution of ciprofloxacin resistance in several microorganisms recovered at the Hospital Clinic–Barcelona. ♦, S. pneumoniae; ■, P. aeruginosa; ▲, E. coli; •, Campylobacter spp.
1. Blázquez, J. 2003. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis. 37: 1201– 1209.
2. Cabrera, R.,, J. Ruiz,, F. Marco,, I. Oliveira,, M. Arroyo,, A. Aladueña,, M. A. Usera,, M. T. Jiménez de Anta,, J. Gascón, and, J. Vila. 2004. Mechanism of resistance to several antimicrobial agents in Salmonella clinical isolates causing traveler’s diarrhea. Antimicrob. Agents Chemother. 48: 3934– 3939.
3. Carmeli, T.,, N. Troillet,, G. M. Eliopoulos, and, M. H. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different anti-pseudomonal agents. Antimicrob. Agents Chemother. 43: 1379– 1382.
4. Chen, D. K.,, A. McGeer, and, J. C. DeAzavedo. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341: 233– 239.
5. Cheung, T. K.,, Y. W. Chu,, M. Y. Chu,, C. H. Ma,, R. W. Yung, and, K. M. Kam. 2005. Plasmid-mediated resistance to ciprofloxacin and cefotaxime in clinical isolates of Salmonella enterica serotype enteritidis in Hong Kong. J. Antimicrob. Chemother. 56: 586– 589.
6. Cirz, R. T.,, J. K. Chin,, D. R. Andes,, V. Crécy-Lagard,, W. A. Craig, and, F. E. Romesberg. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3: e176.
7. Davies, T. A.,, A. Evangelista,, S. Pfleger, et al. 2002. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46: 119– 124.
8. El Amari, E. B.,, E. Chamot,, R. Auckenthaler,, J. C. Pechere, and, C. Van Delden. 2001. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin. Infect. Dis. 33: 1859– 1864.
9. Fridkin, S.,, H. A. Hill,, N. V. Volkova,, J. R. Edwards,, R. M. Lawton,, R. P. Gaynes, and, J. E. McGown. 2002. Temporal changes in prevalence of antimicrobial resistance in 23 U.S Hospitals. Emerg. Infect. Dis. 8: 697– 701.
10. Garau, J.,, M. Xercavins,, M. Rodríguez-Carballeira,, J. R. Gómez-Vera,, I. Coll,, D. Vidal,, T. Llovet, and, A. Ruiz-Bremón. 1999. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob. Agents Chemother. 43: 2736– 2741.
11. González Martín, M. G.,, I. De Miguel,, A. Cañas, and, A. M. Sánchez. 2000. Resistencia a antibióticos en aislamientos clínicos del género Enterococcus. Rev. Esp. Quimioter. 13: 412– 416.
12. Hata, M.,, M. Suzuki,, M. Matsumoto,, M. Takahashi,, K. Sato,, S. Ibe, and, K. Sakae. 2005. Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shigella flexneri 2b. Antimicrob. Agents Chemother. 49: 801– 803.
13. Ho, P. L.,, T. L. Que,, D. N. Tsang,, T. K. Ng,, K. H. Chow, and, W. H. Seto. 1999. Emergence of fluoroquinolone resistance among multiple resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43: 1310– 1313.
14. Ho, P. L.,, T. L. Que,, D. N. Tsang,, T. K. Ng,, K. H. Chow, and, W. H. Seto. 2001. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. J. Antimicrob. Chemother. 48: 731– 734.
15. Hooper, D. C. 2002. Fluoroquinolone resistance among gram-positive cocci. Lancet Infect. Dis. 2: 530– 538.
16. Horcajada, J. P.,, J. Vila,, A. Moreno-Martínez,, J. Ruiz,, J. A. Martínez,, M. Sánchez,, E. Soriano, and, J. Mensa. 2002. Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli alter prolonged administration of ciprofloxacin in patients with prostatitis. J. Antimicrob. Chemother. 49: 55– 59.
17. Jacoby, G. A.,, N. Chow, and, K. B. Waites. 2003. Prevalence of plasmid-mediated quinolone resistance. Antimicrob. Agents Chemother. 47: 559– 562.
18. Jacoby, G. A.,, K. E. Walsh,, D. M. Mills,, V. J. Walker,, H. Oh,, A. Robicsek, and, D. C. Hooper. 2006. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob. Agents Chemother. 50: 1178– 1182.
19. Jeong, J. Y.,, H. J. Yoon, and, E. S. Kim. 2005. Detection of qnr in clinical isolates of Escherichia coli from Korea. Antimicrob. Agents Chemother. 49: 2522– 2524.
20. Jonas, D.,, K. Biehler,, D. Hartung,, B. Spitzmuller, and, F. D. Daschner. 2005. Plasmid-mediated quinolone resistance in isolates obtained in German intensive care units. Antimicrob. Agents Chemother. 49: 773– 775.
21. Karlowsky, J. A.,, D. C. Draghi,, M. E. Jonez,, C. Thornsberry,, I. R. Friedland, and, D. F. Sahm. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa from hospitalised patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47: 1681– 1688.
22. Kern, W. V.,, M. Steib-Bauert,, K. de With,, S. Reuter,, H. Bertz,, U. Frank, and, H. von Baum. 2005. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999–2002. J. Antimicrob. Chemother. 55: 57– 60.
23. Livermore, D.,, D. James,, M. Reacher,, C. Graham,, T. Nichols,, P. Stephens,, A. P. Johnson, and, R. C. George. 2002. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990–1999. Emerg. Infect. Dis. 8: 473– 478.
24. MacDougall, C.,, S. E. Harpe,, J. P. Powell,, C. K. Johnson,, M. B. Edmond, and, R. E. Polk. 2005. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg. Infect. Dis. 11: 1197– 1204.
25. Mammeri, H.,, M. Van De Loo,, L. Poirel, et al. 2005. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob. Agents Chemother. 49: 71– 76.
26. Manjunatha, U. H.,, M. Dalal,, M. Chatterji,, D. R. Radha,, S. S. Winweswariah, and, V. Nagaraja. 2002. Functional characterization of mycobacterial DNA gyrase: an efficient decatenase. Nucleic Acids Res. 30: 2144– 2153.
27. Martínez-Martínez, L. A.,, A. Pascual, and, G. A. Jacoby. 1998. Quinolone resistance from a transfererable plasmad. Lancet 351: 797– 799.
28. Masterton, R. G. 2002. Ciprofloxacin resistance “early-warning” signs from the MYSTIC surveillance programme? J. Antimicrob. Chemother. 49: 215– 224.
29. Meyer, E.,, F. Schwab,, D. Jonas,, H. Ruden,, P. Gastmeier, and, F. D. Daschner. 2005. Temporal changes in bacterial resistance in German intensive care units, 2001–2003: data from the SARI (Surveillance of antimicrobial use and antimicrobial resistance in intensive care units) project. J. Hosp. Infect. 60: 348– 352.
30. Molbak, K.,, P. Gerner-Smidt, and, H. C. Wegener. 2002. Increased quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg. Infect. Dis. 8: 514– 515.
31. Moore, R. A.,, B. Beckthold,, S. Wong,, A. Kureishi, and, L. E. Bryan. 1995. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 39: 107– 111.
32. Nazik, A.,, L. Poirel, and, P. Nordmann. 2005. Further identification of plasmid-mediated quinolone resistance determinant in Enterobacteriaceae in Turkey. Antimicrob. Agents Chemother. 49: 2146– 2147.
33. Neuhauser, M. M.,, R. A. Weisntein,, R. Rydman, and, L. H. Danzinger. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289: 885– 888.
34. Oteo, J.,, E. Lázaro,, F. J. de Abajo,, F. Baquero, and, J. Campos. 2005. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg. Infect. Dis. 11: 546– 553.
35. Phillips, I.,, E. Culebras,, F. Moreno, and, F. Baquero. 1987. Induction of the SOS response by new 4-quinolones. J. Antimicrob. Chemother. 20: 631– 638.
36. Poirel, L.,, A. Liard,, J. M. Rodriguez-Martínez, and, P. Nordmann. 2005a. Vibrionaceae as a possible source of Qnr-like quinolone resistance determinants. J. Antimicrob. Chemother. 56: 1118– 1121.
37. Poirel, L.,, J. M. Rodríguez-Martínez,, H. Mammeri, et al. 2005b. Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob. Agents Chemother. 49: 3523– 3525.
38. Reinert, R. R.,, S. Reinert,, M. van der Linen,, M. Y. Cil,, A. Al-Lahham, and, P. Appelbaum. 2005. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49: 2903– 2913.
39. Ribera, A.,, A. Doménech-Sánchez,, J. Ruiz,, V. J. Benedi,, M. T. Jiménez de Anta, and, J. Vila. 2002a. Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates. Microb. Drug Resist. 8: 245– 251.
40. Ribera, A.,, J. Ruiz,, M. T. Jiménez de Anta, and, J. Vila. 2002b. Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. J. Antimicrob. Chemother. 49: 697– 698.
41. Robicsek, A.,, D. F. Sahm,, J. Strahilevitz,, G. A. Jacoby, and, D. C. Hooper. 2005. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob. Agents Chemother. 49: 3001– 3003.
42. Schofield, M. J., and, P. Hsieh. 2003. DNA mismatch repair: molecular mechanisms and biological function. Annu. Rev. Microbiol. 57: 579– 608.
43. Shannon, K. P., and, G. L. French. 2004. Increasing resistance to antimicrobial agents of gram-negative organisms isolated at a London teaching hospital, 1995–2000. J. Antimicrob. Chemother. 53: 818– 825.
44. Sierra, J. M.,, J. G. Cabeza,, M. Ruiz,, T. Montero,, J. Hernandez,, J. Mensa,, M. Llagostera, and, J. Vila. 2005. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin. Microbiol. Infect. 11: 750– 758.
45. Sierra, J. M.,, F. Marco,, J. Ruiz,, M. T. Jimenez de Anta, and, J. Vila. 2002. Correlation between the activity of different fluoro-quinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus. Clin. Microbiol. Infect. 8: 781– 790.
46. Soto, S. M.,, M. T. Jimenez de Anta, and, J. Vila. 2006. Quinolones induce partial or total loss of pathogenicity islands in uroptahogenic Escherichia coli by SOS-dependent or -independent pathways, respectively. Antimicrob. Agents. Chemother. 50: 649– 653.
47. Tran, J. H.,, G. A. Jacoby, and, D. C. Hooper. 2005a. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 49: 118– 125.
48. Tran, J. H.,, G. A. Jacoby, and, D. C. Hooper. 2005b. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli topoisomerase IV. Antimicrob. Agents. Chemother. 49: 3050– 3052.
49. Tran, J. H., and, G. A. Jacoby. 2002. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl. Acad. Sci. USA 99: 5638– 5642.
50. Ullsperger, C., and, N. R. Cozzarelli. 1996. Contrasting enzymatic activities of topoisomerase IV and DNA gyrase from Escherichia coli. J. Biol. Chem. 271: 31549– 31555.
51. Unal, S.,, R. Masterton, and, H. Goossens. 2004. Bacteraemia in Europe—antimicrobial susceptibility from the MYSTIC surveillance programme. Inter. J. Antimicrob. Agents 23: 155– 163.
52. Unicomb, L.,, J. Ferguson,, T. V. Riley, and, P. Collingnon. 2003. Fluoroquinolone resistance in Campylobacter absent from isolates, Australia. Emerg. Infect. Dis. 9: 1482– 1483.
53. Valdezate, S.,, A. Vindel,, A. Echeita, et al. 2002. Topoisomerase II and IV quinolone-resistance determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrob. Agents Chemother. 46: 665– 671.
54. Valdezate, S.,, A. Vindel,, J. A. Saéz-Nieto,, F. Baquero, and, R. Cantón. 2005. Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains. J. Antimicrob. Chemother. 56: 220– 223.
55. Vila, J., and, S. B. Levy. 2003. Antimicrobial resistance, p. 58– 75. In C. D. Ericsson,, H. L. Dupont, and, R. Steffen (ed.), Travelers’ Diarrhea. BC Decker, Hamilton, Ontario, Canada.
56. Vila, J.,, J. Ruiz,, F. Sánchez,, F. Navarro,, B. Mirelis,, M. T. Jiménez de Anta, and, G. Prats. 1999. Increase in quinolone resistance in Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrob. Agents Chemother. 43: 161– 162.
57. Vila, J. 2005. Fluoroquinolone resistance, p. 41– 52. In D. G. White,, M. N. Alekshun, and, P. F. McDermott (ed.), Frontiers in Antimicrobial Resístanse: A Tribute to Stuart B. Levy. ASM Press, Washington, DC.
58. Wang, M.,, D. F. Sahm,, G. A. Jacoby, and, D. C. Hooper. 2004. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob. Agents Chemother. 48: 1295– 1299.
59. Wang, M.,, J. H. Tran,, G. A. Jacoby,, Y. Zhang,, F. Wang, and, D. C. Hooper. 2003. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob. Agents Chemother. 47: 2242– 2248.
60. Weber, S. G.,, H. S. Gold,, D. C. Hooper,, A. W. Karchmer, and, Y. Carmeli. 2003. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 9: 1415– 1422.
61. Zhao, X., and, K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33 (Suppl 3): S147– S156.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V.